Phase I/II, multicenter, open-label study of intratumoral/intralesional administration of the retinoic acid-inducible gene I (RIG-I) activator MK-4621 in patients with advanced or recurrent tumors

被引：0
作者：
Middleton, M. R. [1 ]
Wermke, M. [2 ]
Calvo, E. [3 ]
Chartash, E. [4 ]
Zhou, H. [4 ]
Zhao, X. [4 ]
Niewel, M. [5 ]
Dobrenkov, K. [4 ]
Moreno, V. [6 ]
机构：
[1] Univ Oxford, Oncol, Oxford, England
[2] Univ Klinikum CG Carus, UCC Early Clin Trial Unit, Dresden, Germany
[3] Hosp Fdn Jimenez Diaz, Clin Res, START Madrid FJD, Madrid, Spain
[4] Merck & Co Inc, Med Oncol, Kenilworth, NJ USA
[5] Merck & Co Inc, Clin, Munich, Germany
[6] Hosp Fdn Jimenez Diaz, Med Oncol, START Madrid FJD, Madrid, Spain
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA16
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and varying degrees of renal function
    Sunil Sharma
    Petronella O. Witteveen
    Martijn P. Lolkema
    Dagmar Hess
    Hans Gelderblom
    Syed A. Hussain
    Maria G. Porro
    Edward Waldron
    Sue-zette Valera
    Song Mu
    Cancer Chemotherapy and Pharmacology, 2015, 75 : 87 - 95
  • [32] A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and varying degrees of renal function
    Sharma, Sunil
    Witteveen, Petronella O.
    Lolkema, Martijn P.
    Hess, Dagmar
    Gelderblom, Hans
    Hussain, Syed A.
    Porro, Maria G.
    Waldron, Edward
    Valera, Sue-zette
    Mu, Song
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (01) : 87 - 95
  • [33] A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and various degrees of hepatic function
    Marije Slingerland
    Dagmar Hess
    Sally Clive
    Sunil Sharma
    Per Sandstrom
    Niklas Loman
    Maria G. Porro
    Song Mu
    Edward Waldron
    Sue-zette Valera
    Hans Gelderblom
    Cancer Chemotherapy and Pharmacology, 2014, 74 : 1089 - 1098
  • [34] Combination of anlotinib and irinotecan in the second-line treatment of patients with advanced colorectal cancer: An open-label, multicenter phase I/II study.
    Zhang, Bo
    Wang, Xi
    Zhu, Lingjun
    Li, Qun
    Liu, Yun
    Qi, Ling
    Shu, Yongqian
    Huang, Jing
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [35] A phase I/II open label, multicenter study to assess the safety, tolerability, pharmacokinetics, and efficacy of HB0028 in patients with advanced solid tumors
    Wang, Jing
    Huang, Yi
    Huang, Manping
    Deng, Jun
    Huang, Si
    Tian, Wenfang
    Liu, Hanchun
    Tang, Yan
    Cao, Bo
    Jiang, Lei
    Jiang, Xiaohui
    Zhao, Ke
    Yang, Runfeng
    Zhu, Xiangyang
    Yang, Yongmin
    Yang, Yang
    Hou, Kexin
    Chen, Juan
    Tang, Yuan
    Zheng, Xiaohui
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [36] Thermal ablation plus toripalimab in patients with advanced hepatocellular carcinoma: Phase I results from a multicenter, open-label, controlled phase I/II trial (IR11330)
    Shi, L.
    Zhou, C.
    Long, X.
    Li, H.
    Chen, C.
    Peng, C.
    Li, P.
    Li, J.
    Gu, S.
    Liang, B.
    Liao, W.
    ANNALS OF ONCOLOGY, 2021, 32 : S826 - S826
  • [37] A phase I, open-label, single-arm study for QT assessment of eribulin mesylate in patients with advanced solid tumors
    Lesimple, Thierry
    Edeline, Julien
    Carrothers, Timothy J.
    Cvitkovic, Frederique
    Darpo, Borje
    Delord, Jean-Pierre
    Lena, Herve
    Penel, Nicolas
    Edwards, Geoff J.
    Law, Kenneth
    Wanders, Jantien
    Kristensen, Allan
    Reyderman, Larisa
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (04) : 900 - 909
  • [38] A phase I, open-label, single-arm study for QT assessment of eribulin mesylate in patients with advanced solid tumors
    Thierry Lesimple
    Julien Edeline
    Timothy J. Carrothers
    Frédérique Cvitkovic
    Borje Darpo
    Jean-Pierre Delord
    Hervé Léna
    Nicolas Penel
    Geoff J. Edwards
    Kenneth Law
    Jantien Wanders
    Allan Kristensen
    Larisa Reyderman
    Investigational New Drugs, 2013, 31 : 900 - 909
  • [39] Safety, tolerability, pharmacokinetics, and antitumor activity of adavosertib in Japanese patients with advanced solid tumors: A phase I, open-label study
    Kondo, Shunsuke
    Katsuya, Yuki
    Yonemori, Kan
    Komuro, Keiko
    Sugeno, Masatoshi
    Kawata, Toshio
    Ghiorghiu, Dana
    Meulendijks, Didier
    Yamamoto, Noboru
    CANCER TREATMENT AND RESEARCH COMMUNICATIONS, 2024, 39
  • [40] Epacadostat plus durvalumab in patients with advanced solid tumors: preliminary results of the ongoing, open-label, phase I/II ECHO-203 study
    Naing, Aung
    Powderly, John D.
    Falchook, Gerald
    Creelan, Benjamin
    Nemunaitis, John
    Lutzky, Jose
    Diab, Adi
    Wang, Judy S.
    Laing, Naomi
    Niewood, Michelle
    Gong, Xiaohua
    Zhou, Gongfu
    Patel, Manish
    CANCER RESEARCH, 2018, 78 (13)
12345